AVONTEC: Results of a multiple dose clinical proof of concept study with its drug candidate AVT-01 decoy ODN
04-Mar-2008 -
Avontec GmbH announced the results of a multiple dose, double-blind, randomized, placebo-controlled, multicenter, multinational, unbalanced, parallel-group comparison study with its lead drug candidate AVT-01 decoy oligonucleotide (AVT-01 decoy ODN) in asthmatic patients. In this study, the ...
chronic inflammation
clinical trials
reductions
+1